Tryptamine Therapeutics Limited (ASX:TYP)

Tryptamine Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021
Revenue	1.58	1.33	-	-	-
Revenue Growth (YoY)	19.17%	-	-	-	-
Cost of Revenue	2.4	2.35	2.62	-	-
Gross Profit	-0.82	-1.02	-2.62	-	-
Selling, General & Admin	4.24	1.7	2.45	4.59	3.84
Research & Development	-	-	-	3.3	1.39
Operating Expenses	4.33	3.5	2.45	8.2	7.89
Operating Income	-5.15	-4.52	-5.07	-8.2	-7.89
Interest Expense	-0.01	-0.65	-0.79	-	-
Interest & Investment Income	0.01	0.02	0	0	0.01
Currency Exchange Gain (Loss)	-0.04	-0.12	-	-0.15	-0.02
EBT Excluding Unusual Items	-5.19	-5.27	-5.85	-8.35	-7.9
Asset Writedown	-0.14	-	-	-	-1.04
Other Unusual Items	-	-2.1	-	-	-
Pretax Income	-5.33	-7.37	-5.85	-8.35	-8.94
Net Income	-5.33	-7.37	-5.85	-8.35	-8.94
Net Income to Common	-5.33	-7.37	-5.85	-8.35	-8.94
Shares Outstanding (Basic)	1,378	507	349	78	51
Shares Outstanding (Diluted)	1,378	507	349	78	51
Shares Change (YoY)	172.04%	45.33%	346.62%	51.73%	-
EPS (Basic)	-0.00	-0.01	-0.02	-0.11	-0.17
EPS (Diluted)	-0.00	-0.01	-0.02	-0.11	-0.17
Free Cash Flow	-7.9	-7.2	-4.03	-6.47	-5.48
Free Cash Flow Per Share	-0.01	-0.01	-0.01	-0.08	-0.11
Gross Margin	-51.65%	-76.85%	-	-	-
Operating Margin	-325.49%	-340.38%	-	-	-
Profit Margin	-337.14%	-555.37%	-	-	-
Free Cash Flow Margin	-499.43%	-542.48%	-	-	-
EBITDA	-5.09	-4.51	-	-	-
D&A For EBITDA	0.05	0.01	-	-	-
EBIT	-5.15	-4.52	-5.07	-8.2	-7.89
Revenue as Reported	1.59	1.34	0	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.